Anteris Technologies Global Corp. (NASDAQ:AVR) Stock Has Average Price Target of $14.00

Shares of Anteris Technologies Global Corp. (NASDAQ:AVR) have been given an average recommendation of “Hold” by the five brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $14.00.

Several research analysts have recently commented on AVR shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 price target on shares of Anteris Technologies Global in a report on Wednesday, October 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Finally, Barclays raised shares of Anteris Technologies Global to a “hold” rating in a report on Wednesday, October 7th.

Anteris Technologies Global Stock Performance

Shares of Anteris Technologies Global stock opened at $5.58 on Friday. Anteris Technologies Global has a one year low of $3.30 and a one year high of $11.06. The company has a market cap of $543.83 million, a price-to-earnings ratio of -2.86 and a beta of 2.02. The business’s 50 day moving average price is $7.30 and its 200 day moving average price is $7.39.

Anteris Technologies Global (NASDAQ:AVR) last issued its earnings results on Tuesday, August 11th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.09). The company had revenue of $1.01 million during the quarter, compared to analysts’ expectations of $1.50 million. Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. During the same quarter in the previous year, the company earned ($0.58) earnings per share. On average, analysts predict that Anteris Technologies Global will post -1.21 EPS for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder L1 Capital Pty Ltd bought 648,455 shares of the firm’s stock in a transaction on Monday, October 5th. The shares were bought at an average cost of $7.51 per share, for a total transaction of $4,869,897.05. Following the acquisition, the insider directly owned 12,778,380 shares of the company’s stock, valued at $95,965,633.80. This trade represents a 5.35% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last quarter, insiders have bought 1,554,730 shares of company stock worth $11,694,513 and have sold 635,459 shares worth $5,855,734. 4.50% of the stock is owned by company insiders.

Institutional Trading of Anteris Technologies Global

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in Anteris Technologies Global in the second quarter valued at approximately $56,846,000. Nantahala Capital Management LLC purchased a new position in Anteris Technologies Global in the second quarter worth approximately $33,325,850. ADAR1 Capital Management LLC purchased a new position in Anteris Technologies Global in the second quarter worth approximately $30,979,000. Perceptive Advisors LLC grew its position in Anteris Technologies Global by 104.4% in the first quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock worth $19,011,000 after acquiring an additional 1,750,000 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new stake in Anteris Technologies Global during the second quarter worth $6,350,000.

Anteris Technologies Global Company Profile

Anteris Technologies Global is a medical device company focused on developing structural heart products for the treatment of heart valve disease. Its primary focus is transcatheter aortic valve replacement (TAVR), a minimally invasive procedure used to replace a diseased aortic valve without traditional open-heart surgery.

The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the function and hemodynamic performance of a healthy human aortic valve.